Allergic bronchopulmonary aspergillosis (ABPA) is a fungus caused by Aspergillus Th2 immune-mediated complex lung disease, most commonly associated with asthma and cystic fibrosis (CF), caused by Aspergillus fumigatus. In recent years, serological markers such as specific IgE and eosinophil counts, together with characteristic radiologic findings, have become established cornerstones of ABPA diagnosis. The combination of corticosteroids and antifungal agents remains a first-line treatment option, however, new biological targeted therapies have been gradually introduced into clinical practice for hormone-dependent and refractory cases and have demonstrated significant clinical efficacy. This article reviews the epidemiological characteristics, pathophysiological mechanisms, clinical manifestations, diagnostic criteria and treatment strategies of ABPA, aiming to provide evidence-based evidence for clinical diagnosis and treatment.

Duo Wang, Jianhua Gong. Research Progress of Allergic Bronchopulmonosis. Frontiers in Medical Science Research (2025), Vol. 7, Issue 5: 18-22. https://doi.org/10.25236/FMSR.2025.070503.

[1] Hinson K F, Moon A J, Plummer N S. Broncho-pulmonary aspergillosis; a review and a report of eight new cases [J]. Thorax, 1952, 7(4): 317-333.

[2] Denton E, Wark P, Hew M. Allergic broncho-pulmonary aspergillosis: Old disease, new frontiers [J]. Respirology (Carlton, Vic), 2024, 29(8): 656-658.

[3] Denning D W, Pleuvry A, Cole D C. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults [J]. Medical mycology, 2013, 51(4): 361-370.

[4] Patel A R, Patel A R, Singh S, et al. Diagnosing Allergic Bronchopulmonary Aspergillosis: A Review [J]. Cureus, 2019, 11(4): e4550.

[5] Chakrabarti A, Sethi S, Raman D S, et al. Eight-year study of allergic bronchopulmonary aspergillosis in an Indian teaching hospital [J]. Mycoses, 2002, 45(8): 295-299.

[6] Agarwal R, Sehgal I S, Muthu V, et al. Allergic Bronchopulmonary Aspergillosis in India [J]. Clinical and Experimental Allergy, 2023, 53(7): 751-764.

[7] Agarwal R, Muthu V, Sehgal I S, et al. Aspergillus Sensitization and Allergic Bronchopulmonary Aspergillosis in Asthmatic Children: A Systematic Review and Meta-Analysis [J]. Diagnostics (Basel, Switzerland), 2023, 13(5).

[8] Oguma T, Taniguchi M, Shimoda T, et al. Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey [J]. Allergology international : official journal of the Japanese Society of Allergology, 2018, 67(1): 79-84.

[9] Kim J H, Jin H J, Nam Y H, et al. Clinical features of allergic bronchopulmonary aspergillosis in Korea [J]. Allergy, asthma & immunology research, 2012, 4(5): 305-308.

[10] Muthu V, Sehgal I S, Prasad K T, et al. Epidemiology and outcomes of allergic bronchopulmonary aspergillosis in the elderly [J]. Mycoses, 2022, 65(1): 71-78.

[11] Kanaujia R, Arora A, Chakrabarti A, et al. Occurrence of Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations in Patients with Allergic Bronchopulmonary Aspergillosis Complicating Asthma [J]. Mycopathologia, 2022, 187(2-3): 147-155.

[12] Chaudhary N, Datta K, Askin F B, et al. Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation [J]. American journal of respiratory and critical care medicine, 2012, 185(3): 301-310.

[13] Tracy M C, Okorie C U A, Foley E A, et al. Allergic Bronchopulmonary Aspergillosis [J]. Journal of fungi (Basel, Switzerland), 2016, 2(2).

[14] Becker K L, Gresnigt M S, Smeekens S P, et al. Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients [J]. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2015, 45(2): 423-437.

[15] Luo Y, Ren J, Liang L, et al. Correlation of Aspergillus fumigatus Sensitization with Mucus Plugging in COPD [J]. International journal of chronic obstructive pulmonary disease, 2025, 20: 57-63.

[16] Zhang C, Jiang Z, Shao C. Clinical characteristics of allergic bronchopulmonary aspergillosis [J]. The clinical respiratory journal, 2020, 14(5): 440-446.

[17] Shi Jing, Liu Xiansheng. Advances in the diagnosis and treatment of allergic bronchopulmonary aspergillosis [J]. Journal of Clinical Internal Medicine, 2023, 40(08): 508-512.

[18] Zeng Y, Xue X, Cai H, et al. Clinical Characteristics and Prognosis of Allergic Bronchopulmonary Aspergillosis: A Retrospective Cohort Study [J]. J Asthma Allergy, 2022, 15: 53-62.

[19] Sehgal I S, Muthu V, Dhooria S, et al. Impact of Bronchiectasis Severity on Clinical Outcomes in Patients With Allergic Bronchopulmonary Aspergillosis: A Retrospective Cohort Study [J]. The journal of allergy and clinical immunology In practice, 2025, 13(5): 1103-1109.

[20] Rosenberg M, Patterson R, Mintzer R, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis [J]. Annals of internal medicine, 1977, 86(4): 405-414.

[21] Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria [J]. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2013, 43(8): 850-873.

[22] Agarwal R, Sehgal I S, Muthu V, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses [J]. The European respiratory journal, 2024, 63(4).

[23] Moss R B. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis [J]. The European respiratory journal, 2014, 43(5): 1487-1500.

[24] Godet C, Couturaud F, Marchand-Adam S, et al. Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial [J]. The European respiratory journal, 2022, 59(6).

[25] Agarwal R, Gupta D, Aggarwal A N, et al. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India [J]. Chest, 2006, 130(2): 442-448.

[26] Easthope S, Jarvis B. Omalizumab [J]. Drugs, 2001, 61(2): 253-260; discussion 261.

[27] Li J X, Fan L C, Li M H, et al. Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature [J]. Respiratory medicine, 2017, 122: 33-42.

[28] Chen P, Yu Y, He L, et al. Efficacy of omalizumab in adult patients with allergic bronchopulmonary aspergillosis: a multicentre study in China [J]. Clinical and experimental medicine, 2024, 24(1): 6.

[29] Jaffe J S, Massanari M. In response to dosing omalizumab in allergic asthma [J]. The Journal of allergy and clinical immunology, 2007, 119(1): 255-256.

[30] Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis [J]. Scientific reports, 2015, 5: 8191.

[31] Ramonell R P, Lee F E-H, Swenson C, et al. Dupilumab Treatment for Allergic Bronchopulmonary Aspergillosis: A Case Series [J]. The Journal of Allergy and Clinical Immunology In Practice, 2019, 8(2): 742-743.

[32] Tolebeyan A, Mohammadi O, Vaezi Z, et al. Mepolizumab As Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases [J]. Cureus, 2020, 12(8): e9684.

[33] Ogata H, Sha K, Kotetsu Y, et al. Tezepelumab Treatment for Allergic Bronchopulmonary Aspergillosis [J]. Respirology Case Reports, 2023, 11(5): e01147.